TL;DR CNBC

People on Novo Nordisk's Wegovy maintain weight loss for up to four years, study says

Publishing timestamp: 2024-05-14 11:16:13

Summary

Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, reducing the risk of heart disease regardless of patient's weight. The findings could help boost coverage for the drug by insurers and governments.

Sentiment: POSITIVE

Tickers: NOVO.B-DK,  LLY,  NVO, 

Keywords: science,  business,  health care industry,  eli lilly and co,  business news,  biotechnology,  biotech and pharmaceuticals,  novo nordisk a/s,  social issues,  pharmaceuticals, 

Source: https://www.cnbc.com/2024/05/14/wegovy-patients-maintain-weight-loss-for-4-years-novo-nordisk-study.html